Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	At-The-Market Equity Program	Betta Pharma Stock Purchase Agreement	Common Stock	Common Stock At-The-Market Equity Program	Common Stock Betta Pharma Stock Purchase Agreement	Additional Paid-In Capital	Additional Paid-In Capital At-The-Market Equity Program	Additional Paid-In Capital Betta Pharma Stock Purchase Agreement	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022				48,966,216
Beginning balance at Dec. 31, 2022	$ 289,234			$ 5			$ 689,256			$ (4,137)	$ (395,890)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net (in shares)					11,186,142
Issuance of common stock, net		$ 57,673						$ 57,672
Exercise of stock options and release of stock units (in shares)				13,096
Exercise of stock options and release of stock units	58			$ 1			58
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding (in shares)				117,745
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding	(110)						(110)
Issuance of common stock under the 2020 ESPP (in shares)				133,784
Issuance of common stock under the 2020 ESPP	368						368
Stock-based compensation	27,235						27,235
Unrealized gain (loss) on marketable securities	4,010									4,010
Net loss	(132,493)										(132,493)
Other (in shares)				50,205
Other	139						139
Ending balance (in shares) at Dec. 31, 2023				60,467,188
Ending balance at Dec. 31, 2023	246,114			$ 6			774,618			(127)	(528,383)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net (in shares)					4,132,122	5,567,928
Issuance of common stock, net		$ 24,370	$ 20,000			$ 1		$ 24,370	$ 19,999
Exercise of stock options and release of stock units (in shares)				149,818
Exercise of stock options and release of stock units	778						778
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding (in shares)				176,819
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding	(194)						(194)
Issuance of common stock under the 2020 ESPP (in shares)				110,895
Issuance of common stock under the 2020 ESPP	382						382
Stock-based compensation	29,662						29,662
Unrealized gain (loss) on marketable securities	180									180
Net loss	(105,316)										(105,316)
Other (in shares)				21,129
Other	10						10
Ending balance (in shares) at Dec. 31, 2024				70,625,899
Ending balance at Dec. 31, 2024	$ 215,986			$ 7			$ 849,625			$ 53	$ (633,699)